Conclusion: Our findings suggest that ATL III is a therapeutic drug for the treatment of NAFLD and such protective effect is mediated by activating hepatic AdipoR1-mediated AMPK/SIRT1 signaling pathway. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.